Melanoma drug combo study halted before full results

NCT ID NCT01604889

First seen Apr 24, 2026 · Last updated May 15, 2026 · Updated 4 times

Summary

This study tested a combination of two drugs—ipilimumab (an approved immunotherapy) and epacadostat (an experimental pill)—in people with advanced melanoma that could not be removed by surgery or had spread. The goal was to see if the combination was safe and worked better than ipilimumab alone. Only the first safety part was completed; the study was stopped early for business reasons, not because of safety concerns. About 50 adults took part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Study site

    Los Angeles, California, United States

  • Study site

    Miami, Florida, United States

  • Study site

    Tampa, Florida, United States

  • Study site

    Chicago, Illinois, United States

  • Study site

    Durham, North Carolina, United States

  • Study site

    Philadelphia, Pennsylvania, United States

  • Study site

    Pittsburgh, Pennsylvania, United States

Conditions

Explore the condition pages connected to this study.